{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:13:29Z","timestamp":1793981609574,"version":"4.8.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"SRM Institute of Science & Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"DOI":"10.1186\/s13065-025-01666-0","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T06:33:43Z","timestamp":1763188423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Design and validation of a robust stability-indicating reversed-phase HPLC method for quantification of mesalamine in formulated drug products"],"prefix":"10.1186","volume":"19","author":[{"given":"Ashish Sriram","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2404-6268","authenticated-orcid":false,"given":"Manimaran","family":"Vasanthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,15]]},"reference":[{"key":"1666_CR1","doi-asserted-by":"crossref","unstructured":"M\u2019Koma A. Clinical diagnosis and Phar-maceutical management of inflammatory bowel disease. Med Res Arch. 2023;11.","DOI":"10.18103\/mra.v11i1.3135"},{"key":"1666_CR2","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s40262-018-0639-4","volume":"57","author":"LJJ Derijks","year":"2018","unstructured":"Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical Pharmacokinetic and pharmacodynamic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2018;57:1075\u2013106.","journal-title":"Clin Pharmacokinet"},{"key":"1666_CR3","doi-asserted-by":"publisher","first-page":"11259","DOI":"10.3390\/ijms252011259","volume":"25","author":"WK Mousa","year":"2024","unstructured":"Mousa WK, Al Ali A. The gut Microbiome advances precision medicine and diagnostics for inflammatory bowel diseases. Int J Mol Sci. 2024;25:11259.","journal-title":"Int J Mol Sci"},{"key":"1666_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2174\/0115734129308140240715052552","volume":"20","author":"NA Chaudhari","year":"2024","unstructured":"Chaudhari NA, Ranpise NS. Determination of Mesalamine in bulk and suppository dosage forms through the development and validation of Stability-indicating RP-HPLC method. Curr Pharm Anal. 2024;20:433\u201343.","journal-title":"Curr Pharm Anal"},{"key":"1666_CR5","unstructured":"Kerketta GS. A crucial component of pharmaceutical quality. as-surance is drug stability testing. 2023."},{"key":"1666_CR6","first-page":"821","volume":"28","author":"MSS Shinde","year":"2025","unstructured":"Shinde MSS, Khulbe P. Comprehensive validation of analytical methods using A Risk-Based approach: application to RP-HPLC and UV techniques for methotrexate. Am J Psychiatr Rehabil. 2025;28:821\u201331.","journal-title":"Am J Psychiatr Rehabil"},{"key":"1666_CR7","first-page":"71","volume":"4","author":"AK Moharana","year":"2011","unstructured":"Moharana AK, Banerjee M, Sahoo CK, Kanta N. Development and validation of RP-HPLC method for Mesalamine. Asian J Pharm Clin Res. 2011;4:71\u20133.","journal-title":"Asian J Pharm Clin Res"},{"key":"1666_CR8","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.5740\/jaoacint.11-255","volume":"96","author":"MI Walash","year":"2013","unstructured":"Walash MI, Belal F, El-Enany N, Eid M, El-Shaheny RN. Simultaneous determination of Floctafenine and its hydrolytic degradation product Floctafenic acid using micellar liquid chromatography with applications to tablets and human plasma. J AOAC Int. 2013;96:1315\u201324.","journal-title":"J AOAC Int"},{"key":"1666_CR9","doi-asserted-by":"crossref","unstructured":"Huynh-Ba K, Zahn M. Understanding ICH guidelines applicable to stability testing. Handbook of stability testing in pharmaceutical development: regulations, methodologies, and best practices. Springer; 2009. pp. 21\u201341.","DOI":"10.1007\/978-0-387-85627-8_3"},{"key":"1666_CR10","unstructured":"ICHHT Guideline. Validation of analytical procedures: text and methodology. Q2 (R1). 2005;1:05."},{"key":"1666_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.trac.2004.04.001","volume":"23","author":"I Taverniers","year":"2004","unstructured":"Taverniers I, De Loose M, Van Bockstaele E. Trends in quality in the analytical laboratory. II. Analytical method validation and quality assurance. TRAC Trends Anal Chem. 2004;23:535\u201352.","journal-title":"TRAC Trends Anal Chem"},{"key":"1666_CR12","first-page":"19","volume":"3","author":"AK Moharana","year":"2011","unstructured":"Moharana AK, Banerjee M, Panda S, Muduli JN. Development and validation of UV spectrophotometric method for the determination of Mesalamine in bulk and tablet formulation. Int J Pharm Pharm Sci. 2011;3:19\u201321.","journal-title":"Int J Pharm Pharm Sci"},{"key":"1666_CR13","first-page":"4","volume":"62","author":"S Chandran","year":"2007","unstructured":"Chandran S, Singh RSP. Comparison of various international guidelines for analytical method validation. Die Pharmazie-An Int J Pharm Sci. 2007;62:4\u201314.","journal-title":"Die Pharmazie-An Int J Pharm Sci"},{"key":"1666_CR14","doi-asserted-by":"crossref","unstructured":"Subash P, Kumar KKS, Rao KS, Khute S. Advanced chromatography analytical methods for the isolation and identification of natural drug molecules. 2025.","DOI":"10.5772\/intechopen.1007501"},{"key":"1666_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.sajb.2022.05.044","volume":"151","author":"A Awasthi","year":"2022","unstructured":"Awasthi A, Kumar A, Kumar R, Vishwas S, Khursheed R, Kaur J, et al. RP-HPLC method development and validation for simultaneous Estimation of Mesalamine and Curcumin in bulk form as well as nanostructured lipid carriers. South Afr J Bot. 2022;151:529\u201337.","journal-title":"South Afr J Bot"}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-025-01666-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-025-01666-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-025-01666-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T20:04:53Z","timestamp":1763409893000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcchem.biomedcentral.com\/articles\/10.1186\/s13065-025-01666-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1666"],"URL":"https:\/\/doi.org\/10.1186\/s13065-025-01666-0","relation":{},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]},"assertion":[{"value":"17 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical information available.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study does not involve human participants, identifiable personal data, or clinical images requiring consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This research paper was wholly composed by the authors without the use of generative AI or AI-assisted writing tools. The writers have independently developed all of the content, which encompasses data analysis, interpretation, and paper composition.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI in scientific writing"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"303"}}